23 Feb Cynata Therapeutics
Kilian Kelly, Ph.D., CEO
Oct. 8 | 10:45am | FLW Ballroom F
Melbourne, Australia
(ASX:CYP)
Cynata Therapeutics Limited is focused on the commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology, Cymerus™. The Cymerus platform enables scalable manufacture of mesenchymal stem cell (MSC)-based therapeutic products. The primary advantage of the Cymerus platform is its ability to produce an effectively limitless quantity of consistent, high quality MSCs from a single blood donation. This avoids challenges associated with conventional MSC manufacturing methods, including the need for new donations from different donors on an ongoing basis, which is associated with substantial variability and potential impacts on MSC functionality. Cynata’s initial clinical trial in GvHD, which has led to two publications in Nature Medicine, was the first ever completed clinical trial with iPSC-derived cells. There are now four active Cymerus MSC clinical programs (GvHD, osteoarthritis, diabetic foot ulcers and kidney transplantation), with results of three randomized controlled trials expected between late 2024 and early 2026.
